Common questions about Mektovi (FAQ)
Q: What is the difference between Mektovi and other targeted therapies?
The official product information describes Mektovi as a targeted therapy that functions as a MEK Kinase Inhibitor. This means the drug works by blocking the activity of the MEK proteins, which are important signaling components in cancer cells. It is authorized only for use in combination with another medicine that blocks the upstream BRAF protein, creating a dual blockade on the same pathway.
Q: Are there any common over-the-counter medicines that interact with Mektovi?
Official drug labels generally state that patients should inform their healthcare provider about all products being taken, including over-the-counter medicines, vitamins, and herbal supplements. This is necessary because Mektovi is cleared from the body through specific metabolic pathways, which can be affected by other compounds. The provider can assess the potential for interactions between Mektovi and other compounds.
Q: Are there specific foods or drinks that should be avoided while taking Mektovi?
Because Mektovi is always used in combination with encorafenib, official sources recommend that grapefruit and grapefruit juice should be avoided. Avoiding these products helps prevent a potential increase in the blood levels of the companion drug, encorafenib. Mektovi tablets themselves may be taken with or without other foods.
Q: What are the long-term effects of taking Mektovi?
The safety profile of Mektovi covers the entire duration of treatment, which for some patients can last for multiple years. Known serious effects include potential Cardiomyopathy (heart muscle problems) and Ocular Toxicities (eye problems). These risks are associated with warnings that mandate ongoing monitoring throughout the treatment course.
Q: What if I experience nausea when taking Mektovi?
Nausea is documented as a very common side effect of Mektovi in clinical studies. Regulatory information indicates that this symptom should be discussed with the healthcare provider. The healthcare provider may discuss management strategies, such as anti-nausea medicine or eating adjustments, as nausea may sometimes be worse when the medicine is taken on an empty stomach.
Q: Can Mektovi be used in patients with pre-existing heart conditions?
Official guidance states that Mektovi's safety is not established in patients whose heart function (measured by Left Ventricular Ejection Fraction, or LVEF) is below a certain limit. Monitoring of patients with existing cardiovascular risk factors is officially mandated throughout the treatment. Eligibility for treatment is based on an assessment of pre-existing conditions.
Q: Are there any known interactions between Mektovi and birth control pills?
Mektovi is used in combination with encorafenib, and coadministration of encorafenib with hormonal contraceptives should be avoided according to official warnings. Regulatory documents stipulate that females of reproductive potential must use an effective non-hormonal method of contraception throughout treatment and for a specified time afterward.
Q: How do doctors check if Mektovi is working?
Clinical trials measure treatment effectiveness using metrics such as the Objective Response Rate (ORR) and the Time to Response. Treatment is typically continued until clinical signs of disease progression are noted. The treating physician determines the appropriate monitoring schedule based on the patient's status.
Q: Does Mektovi require special handling?
Official labeling states that Mektovi should be stored in the container it was dispensed in, kept tightly closed, and out of the reach of children. Unused or expired tablets must be disposed of according to local guidance, such as through a medicine take-back program. This ensures household safety and maintains product quality.
Q: How long does it usually take for Mektovi to start working?
Clinical study data describes the time until initial tumor response. In the key trial, the median time to response was reported to be 1.8 months. This represents the median amount of time for tumors to show a pre-defined reduction (shrinkage or disappearance) after the initiation of combination treatment.
Q: Is it okay to drink alcohol in moderation while taking Mektovi?
No clinically significant interaction has been documented between Mektovi (binimetinib) and ethyl alcohol (ethanol) in regulatory or drug interaction databases. Patients are encouraged to discuss the use of alcohol with their treating physician to ensure alignment with their overall medical plan.
Q: Does Mektovi affect men and women differently?
The only difference noted in official regulatory documents relates to embryo-fetal toxicity. Because Mektovi may cause harm to a fetus, regulatory documents stipulate that females of reproductive potential must use effective non-hormonal contraception during therapy. No other general differences in how Mektovi affects men and women are explicitly stated in efficacy or toxicity summaries.
Q: Is it common to have skin changes while on Mektovi?
Yes, skin changes are common while taking Mektovi. Official safety information lists Rash as a very common adverse reaction, meaning it affects more than 1 in 10 people. Other skin-related effects noted in regulatory documents include dry skin and changes to moles or sunspots.
Q: Does Mektovi cause weight loss or gain?
Official safety documentation notes that changes in body weight may occur. Potential side effects that have been reported include unusual weight gain or loss and rapid weight gain.
Q: Can Mektovi affect blood sugar levels?
Official safety information lists high blood sugar levels, known medically as hyperglycemia, as a potential adverse reaction or laboratory abnormality associated with the medication. The treating physician may consider closer blood glucose monitoring for patients with pre-existing diabetes or risk factors.
Q: Are there any limitations on physical activity while taking Mektovi?
Mektovi is associated with the risk of muscle problems (such as rhabdomyolysis) and an increase in Creatine Kinase (CK) levels, which require monitoring. Due to these risks, patients should report any intense physical activity or muscle pain experienced to their physician.
Q: Can I travel while on Mektovi treatment?
Since Mektovi is an oral tablet, it does not require refrigeration or infusion and can typically be taken at home or on the go. Patients are advised to ensure the tablets are kept stored properly at room temperature and maintain their scheduled dosing times while traveling.
